GVS advice avacopan (Tavneos®)
The National Health Care Institute has completed its assessment whether the product avacopan (Tavneos®) can be included in the Medicine Reimbursement System (GVS). Avacopan is indicated for the treatment of granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). The National Health Care Institute advises the Minister not to include avacopan in the GVS.
Indication for which reimbursement is requested
Avacopan (Tavneos®), in combination with a rituximab regimen or cyclophosphamide regimen, is indicated for the treatment of adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
National Health Care Institute's advice
The National Health Care Institute advises the Minister not to include avacopan (Tavneos®) in the GVS. The product cannot be placed on List 1A and a review should be carried out to determine whether avacopan is eligible for inclusion on List 1B.